Aastrom Biosciences, Inc. Announces Appointment of Joyce L. Frey-Vasconcells, Ph.D. to Scientific Advisory Board
Published: Oct 30, 2012
ANN ARBOR, Mich., Oct. 29, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that cell therapy regulatory and development expert Joyce L. Frey-Vasconcells, Ph.D. has been appointed to the company's Scientific Advisory Board (SAB). Dr. Frey-Vasconcells is considered one of the foremost regulatory experts for cell therapies, tissues and gene therapies.